Mohammed Elmourtada Abdulgayoom: Exploring Hyperbaric Oxygen Therapy in Sickle Cell Disease
Mohammed Elmourtada Abdulgayoom, Clinical Hematology Specialist at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Hemoglobin, adding։
“I am pleased to share our newly published narrative review in Hemoglobin: Hyperbaric Oxygen Therapy in Sickle Cell Disease: A Narrative Review of Mechanisms, Clinical Applications, and Future Directions.
In this review, we explored the biological rationale and current clinical evidence for hyperbaric oxygen therapy (HBOT) as a potential adjunctive approach in selected complications of sickle cell disease, including vaso-occlusive pain, avascular necrosis, chronic leg ulcers, ophthalmic ischemia, and priapism.
While HBOT may improve tissue oxygenation and potentially reduce ischemia–reperfusion injury, the available evidence remains limited to case reports, small series, and early-phase studies.
Therefore, its role should currently be viewed as investigational and complementary to standard multidisciplinary care, rather than a routine treatment.
Further prospective and controlled studies are needed to define the patients most likely to benefit, optimal treatment protocols, and safety considerations in sickle cell disease.
Grateful to my co-authors for their valuable contributions: Awni Alshurafa, Jamil R Wafi, Tarek Abouzeid, Jaffer Altooq, and Mohamed A. Yassin.”
Title: Hyperbaric Oxygen Therapy in Sickle Cell Disease: A Narrative Review of Mechanisms, Clinical Applications, and Future Directions
Authors: Awni Alshurafa, Mohammed Abdulgayoom, Jamil R Wafi, Tarek Abouzeid, Jaffer Altooq,Mohamed A. Yassin

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support